Engineered probiotics to reduce Clostridia perfringes and prevent necrotic enteritis in chicken
Award amount
$106,500Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Agriculture
- Branch
- Not reported
- Recipient company
- General Probiotics Inc
- Proposal award date
- 2019-07-29
- Contract end date
- 2020-03-31
- UEI
- MM12NKQEXJN7
- Solicitation number
- USDA-NIFA-SBIR-006649
- Topic code
- 8.3
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase I: Antiviral and Anti-inflammatory Live Biotherapeutics (COVID-19)
- Live therapeutics for prevention and control of necrotic enteritis associated with Clostridia perfringens in poultry
- SBIR Phase II: New Antimicrobial Technologies to Eliminate Salmonella Carriage in Poultry
- SBIR Phase I: New antibiotic technologies to eliminate Salmonella carriage in poultry
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Beyond the yolk – A replacement for animal-based product semen extenders
- CoopAEye: A low-cost artificial intelligence enabled camera system for complete commercial poultry house coverage
- A multivalent bovine respiratory disease vaccine built on the live-attenuated BoHV-1 R2 platform
- Use of Real-Time Video to Determine Bovine Embryo Sex
- Pen-Side Multi-Pooled Diagnostics With Centrifugal Microfluidics For Bovine Viral Diarrhea Virus
Research funding history
5 SBIR/STTR records share this UEI (2016–2020). Reported award amounts total $1,789,225. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: National Science Foundation, Department of Agriculture